Underlying Pharmacological Mechanisms of Psilocin-induced Broadband Desynchronization and Disconnection of EEG in Rats

Overview

Journal Front Neurosci

Date 2023 Jul 10

PMID 37425017

Authors

Filip Tyls

cestmir Vejmola

Vlastimil Koudelka

Vaclava Piorecka

Lukas Kaderabek

Marcel Bochin

Tomas Novak

Martin Kuchar

Zdenka Bendova

Martin Brunovsky

Jiri Horacek

Tomas Paleni cek

Affiliations

Soon will be listed here.

Abstract

Introduction: Psilocybin is one of the most extensively studied psychedelic drugs with a broad therapeutic potential. Despite the fact that its psychoactivity is mainly attributed to the agonism at 5-HT receptors, it has high binding affinity also to 5-HT and 5-HT receptors and indirectly modulates the dopaminergic system. Psilocybin and its active metabolite psilocin, as well as other serotonergic psychedelics, induce broadband desynchronization and disconnection in EEG in humans as well as in animals. The contribution of serotonergic and dopaminergic mechanisms underlying these changes is not clear. The present study thus aims to elucidate the pharmacological mechanisms underlying psilocin-induced broadband desynchronization and disconnection in an animal model.

Methods: Selective antagonists of serotonin receptors (5-HT WAY100635, 5-HT MDL100907, 5-HT SB242084) and antipsychotics haloperidol, a D antagonist, and clozapine, a mixed D and 5-HT receptor antagonist, were used in order to clarify the underlying pharmacology.

Results: Psilocin-induced broadband decrease in the mean absolute EEG power was normalized by all antagonists and antipsychotics used within the frequency range 1-25 Hz; however, decreases in 25-40 Hz were influenced only by clozapine. Psilocin-induced decrease in global functional connectivity and, specifically, fronto-temporal disconnection were reversed by the 5-HT antagonist while other drugs had no effect.

Discussion: These findings suggest the involvement of all three serotonergic receptors studied as well as the role of dopaminergic mechanisms in power spectra/current density with only the 5-HT receptor being effective in both studied metrics. This opens an important discussion on the role of other than 5-HT-dependent mechanisms underlying the neurobiology of psychedelics.

Citing Articles

Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons.

Petruskova A, Guhathakurta D, Akdas E, Perello-Amoros B, Frischknecht R, Weiss E J Neurochem. 2025; 169(3):e70020.

PMID: 40022486 PMC: 11871419. DOI: 10.1111/jnc.70020.

Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.

Szpregiel I, Bysiek A Pharmacol Rep. 2024; 76(6):1297-1304.

PMID: 39412581 PMC: 11582295. DOI: 10.1007/s43440-024-00660-y.

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.

Haniff Z, Bocharova M, Mantingh T, Rucker J, Velayudhan L, Taylor D Pharmacol Ther. 2024; 258:108641.

PMID: 38583670 PMC: 11847495. DOI: 10.1016/j.pharmthera.2024.108641.

References

Muthukumaraswamy S, Carhart-Harris R, Moran R, Brookes M, Williams T, Errtizoe D . Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci. 2013; 33(38):15171-83. PMC: 6618409. DOI: 10.1523/JNEUROSCI.2063-13.2013. View

GASTAUT H, Ferrer S, Castells C, LESEVRE N, LUSCHNAT K . [Effect of the d-lysergic acid diethylamide on the psychic functions and on electroencephalogram]. Confin Neurol. 1953; 13(2):102-20. View

Ouagazzal A, Grottick A, Moreau J, Higgins G . Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology. 2001; 25(4):565-75. DOI: 10.1016/S0893-133X(01)00282-2. View

Tyls F, Palenicek T, Kaderabek L, Lipski M, Kubesova A, Horacek J . Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behav Pharmacol. 2015; 27(4):309-20. DOI: 10.1097/FBP.0000000000000198. View

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R . Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021; 384(15):1402-1411. DOI: 10.1056/NEJMoa2032994. View

Castro-Zaballa S, Cavelli M, Gonzalez J, Monti J, Falconi A, Torterolo P . EEG dissociation induced by muscarinic receptor antagonists: Coherent 40 Hz oscillations in a background of slow waves and spindles. Behav Brain Res. 2018; 359:28-37. DOI: 10.1016/j.bbr.2018.10.016. View

Carter O, Burr D, Pettigrew J, Wallis G, Hasler F, Vollenweider F . Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005; 17(10):1497-508. DOI: 10.1162/089892905774597191. View

Jakab R, Goldman-Rakic P . 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A. 1998; 95(2):735-40. PMC: 18490. DOI: 10.1073/pnas.95.2.735. View

Mahapatra A, Gupta R . Role of psilocybin in the treatment of depression. Ther Adv Psychopharmacol. 2017; 7(1):54-56. PMC: 5228719. DOI: 10.1177/2045125316676092. View

10.

Moreau A, Amar M, Le Roux N, Morel N, Fossier P . Serotoninergic fine-tuning of the excitation-inhibition balance in rat visual cortical networks. Cereb Cortex. 2009; 20(2):456-67. DOI: 10.1093/cercor/bhp114. View

11.

Nichols D . Psychedelics. Pharmacol Rev. 2016; 68(2):264-355. PMC: 4813425. DOI: 10.1124/pr.115.011478. View

12.

Glennon R, Titeler M, McKenney J . Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984; 35(25):2505-11. DOI: 10.1016/0024-3205(84)90436-3. View

13.

SHAGASS C . Effects of LSD on somatosensory and visual evoked responses and on the EEG in man. Recent Adv Biol Psychiatry. 1966; 9:209-27. DOI: 10.1007/978-1-4684-8228-7_15. View

14.

Friston K, Frith C . Schizophrenia: a disconnection syndrome?. Clin Neurosci. 1995; 3(2):89-97. View

15.

Carhart-Harris R, Friston K . The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas. Brain. 2010; 133(Pt 4):1265-83. PMC: 2850580. DOI: 10.1093/brain/awq010. View

16.

Tyls F, Palenicek T, Horacek J . Psilocybin--summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014; 24(3):342-56. DOI: 10.1016/j.euroneuro.2013.12.006. View

17.

Riba J, Anderer P, Morte A, Urbano G, Jane F, Saletu B . Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol. 2002; 53(6):613-28. PMC: 1874340. DOI: 10.1046/j.1365-2125.2002.01609.x. View

18.

Amargos-Bosch M, Bortolozzi A, Puig M, Serrats J, Adell A, Celada P . Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex. 2004; 14(3):281-99. DOI: 10.1093/cercor/bhg128. View

19.

Meldrum B, Naquet R . Effects of psilocybin, dimethyltryptamine, mescaline and various lysergic acid derivatives on the EEG and on photically induced epilepsy in the baboon (Papio papio). Electroencephalogr Clin Neurophysiol. 1971; 31(6):563-72. DOI: 10.1016/0013-4694(71)90072-1. View

20.

Pallavicini C, Cavanna F, Zamberlan F, de la Fuente L, Ilksoy Y, Perl Y . Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings. J Psychopharmacol. 2021; 35(4):406-420. DOI: 10.1177/0269881120981384. View